Author name: Ying Mak

Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib Digital Measures that Matter Cambridge Cognition congratulates Bristol Myers Squibb for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium) and the exciting results published recently in The American Journal of Psychiatry1 showcasing the use of CANTAB® in two Phase III […]

Enhancing Patient Outcomes in ADRD Digital Measures that Matter As the landscape for Alzheimer’s Disease and Related Dementias (ADRD) treatment evolves, it’s crucial to align clinical research with the experiences and needs of patients and their care partners. The Digital Medicine Society’s (DiMe) Core Digital Measures of ADRD conceptual model provides a patient-centred framework for

Exploring Innovation in Alzheimer’s Disease Research Highlights from CTAD 2024 17th Clinical Trials on Alzheimer’s Disease (CTAD) Madrid (Spain) October 29 – November 1, 2024 Last week, our team travelled to Madrid to participate in the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, where we had the opportunity to present our latest research and

CTAD24 | Posters & Content Madrid, Spain | 29 October – 1 November 2024 This week, our team traveled to Madrid to attend CTAD 2024, where they presented several posters and hosted a session on Validating Speech-Based Biomarkers for Measuring Disease Progression in Alzheimer’s Disease (AD). These materials are now available for you to access

CTAD24 | Clinical Trials on Alzheimer’s Disease Madrid, Spain | 29 October – 1 November 2024 Be the first to gain access to new data and insights, presented at CTAD24. Access Posters This year at CTAD, we can’t wait to share our latest research with you. There will be four posters, with Michael Spilka, PhD

Revolutionizing Clinical Trial Central Monitoring: Automated Quality Assurance for Faster, Scalable Monitoring by Rachel Newsome, PhD Tuesday 22nd October at 15:45  Accurate administration of rater-based clinical instruments, such as the Clinical Dementia Rating (CDR), is critical for reliable clinical outcomes in Alzheimer’s Disease (AD) trials. However, existing gold-standard quality assurance (QA) processes rely heavily or

We’re thrilled to have presented our latest research at the ISCTM Autumn Meeting on 12-13 September 2024. Rachel Newsome, PhD shared research into the future of clinical trials with recent validation of AQUA, innovation in cognitive assessments, and cutting-edge methodologies. Download poster If you have any questions or would like to discuss any of our